PubMed:19099590
Annnotations
PMID_GLOBAL
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 79-94 | DiseaseOrPhenotypicFeature | denotes | prostate cancer | 0008315 |
| T2 | 202-217 | DiseaseOrPhenotypicFeature | denotes | prostate cancer | 0008315 |
| T3 | 333-348 | DiseaseOrPhenotypicFeature | denotes | prostate cancer | 0008315 |
| T4 | 557-572 | DiseaseOrPhenotypicFeature | denotes | prostate cancer | 0008315 |
| T5 | 657-672 | DiseaseOrPhenotypicFeature | denotes | prostate cancer | 0008315 |
| T6 | 847-862 | DiseaseOrPhenotypicFeature | denotes | prostate cancer | 0008315 |
| T7 | 933-948 | DiseaseOrPhenotypicFeature | denotes | prostate cancer | 0008315 |
| T8 | 1136-1151 | DiseaseOrPhenotypicFeature | denotes | prostate cancer | 0008315 |
| T9 | 1360-1375 | DiseaseOrPhenotypicFeature | denotes | prostate cancer | 0008315 |
| T10 | 1601-1616 | DiseaseOrPhenotypicFeature | denotes | prostate cancer | 0008315 |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-95 | Sentence | denotes | Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. |
| TextSentencer_T2 | 96-107 | Sentence | denotes | BACKGROUND: |
| TextSentencer_T3 | 108-218 | Sentence | denotes | Inflammation has been implicated as an etiological factor in several human cancers, including prostate cancer. |
| TextSentencer_T4 | 219-354 | Sentence | denotes | Allelic variants of the genes involved in inflammatory pathways are logical candidates as genetic determinants of prostate cancer risk. |
| TextSentencer_T5 | 355-578 | Sentence | denotes | The purpose of this study was to investigate whether single nucleotide polymorphisms of genes that lead to increased levels of pro-inflammatory cytokines and chemokines are associated with an increased prostate cancer risk. |
| TextSentencer_T6 | 579-587 | Sentence | denotes | METHODS: |
| TextSentencer_T7 | 588-910 | Sentence | denotes | A case-control study design was used to test the association between prostate cancer risk and the polymorphisms TNF-A-308 A/G (rs 1800629), RANTES-403 G/A (rs 2107538), IL1-A-889 C/T (rs 1800587) and MCP-1 2518 G/A (rs 1024611) in 296 patients diagnosed with prostate cancer and in 311 healthy controls from the same area. |
| TextSentencer_T8 | 911-919 | Sentence | denotes | RESULTS: |
| TextSentencer_T9 | 920-1094 | Sentence | denotes | Diagnosis of prostate cancer was significantly associated with TNF-A GA + AA genotype (OR, 1.61; 95% CI, 1.09-2.64) and RANTES GA + AA genotype (OR, 1.44; 95% CI, 1.09-2.38). |
| TextSentencer_T10 | 1095-1223 | Sentence | denotes | A alleles in TNF-A and RANTES influenced prostate cancer susceptibility and acted independently of each other in these subjects. |
| TextSentencer_T11 | 1224-1309 | Sentence | denotes | No epistatic effect was found for the combination of different polymorphisms studied. |
| TextSentencer_T12 | 1310-1414 | Sentence | denotes | Finally, no overall association was found between prostate cancer risk and IL1-A or MCP-1 polymorphisms. |
| TextSentencer_T13 | 1415-1426 | Sentence | denotes | CONCLUSION: |
| TextSentencer_T14 | 1427-1629 | Sentence | denotes | Our results and previously published findings on genes associated with innate immunity support the hypothesis that polymorphisms in proinflammatory genes may be important in prostate cancer development. |
| T1 | 0-95 | Sentence | denotes | Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. |
| T2 | 96-107 | Sentence | denotes | BACKGROUND: |
| T3 | 108-218 | Sentence | denotes | Inflammation has been implicated as an etiological factor in several human cancers, including prostate cancer. |
| T4 | 219-354 | Sentence | denotes | Allelic variants of the genes involved in inflammatory pathways are logical candidates as genetic determinants of prostate cancer risk. |
| T5 | 355-578 | Sentence | denotes | The purpose of this study was to investigate whether single nucleotide polymorphisms of genes that lead to increased levels of pro-inflammatory cytokines and chemokines are associated with an increased prostate cancer risk. |
| T6 | 579-587 | Sentence | denotes | METHODS: |
| T7 | 588-910 | Sentence | denotes | A case-control study design was used to test the association between prostate cancer risk and the polymorphisms TNF-A-308 A/G (rs 1800629), RANTES-403 G/A (rs 2107538), IL1-A-889 C/T (rs 1800587) and MCP-1 2518 G/A (rs 1024611) in 296 patients diagnosed with prostate cancer and in 311 healthy controls from the same area. |
| T8 | 911-919 | Sentence | denotes | RESULTS: |
| T9 | 920-1094 | Sentence | denotes | Diagnosis of prostate cancer was significantly associated with TNF-A GA + AA genotype (OR, 1.61; 95% CI, 1.09-2.64) and RANTES GA + AA genotype (OR, 1.44; 95% CI, 1.09-2.38). |
| T10 | 1095-1223 | Sentence | denotes | A alleles in TNF-A and RANTES influenced prostate cancer susceptibility and acted independently of each other in these subjects. |
| T11 | 1224-1309 | Sentence | denotes | No epistatic effect was found for the combination of different polymorphisms studied. |
| T12 | 1310-1414 | Sentence | denotes | Finally, no overall association was found between prostate cancer risk and IL1-A or MCP-1 polymorphisms. |
| T13 | 1415-1426 | Sentence | denotes | CONCLUSION: |
| T14 | 1427-1629 | Sentence | denotes | Our results and previously published findings on genes associated with innate immunity support the hypothesis that polymorphisms in proinflammatory genes may be important in prostate cancer development. |
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-95 | Sentence | denotes | Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. |
| T2 | 96-107 | Sentence | denotes | BACKGROUND: |
| T3 | 108-218 | Sentence | denotes | Inflammation has been implicated as an etiological factor in several human cancers, including prostate cancer. |
| T4 | 219-354 | Sentence | denotes | Allelic variants of the genes involved in inflammatory pathways are logical candidates as genetic determinants of prostate cancer risk. |
| T5 | 355-578 | Sentence | denotes | The purpose of this study was to investigate whether single nucleotide polymorphisms of genes that lead to increased levels of pro-inflammatory cytokines and chemokines are associated with an increased prostate cancer risk. |
| T6 | 579-587 | Sentence | denotes | METHODS: |
| T7 | 588-910 | Sentence | denotes | A case-control study design was used to test the association between prostate cancer risk and the polymorphisms TNF-A-308 A/G (rs 1800629), RANTES-403 G/A (rs 2107538), IL1-A-889 C/T (rs 1800587) and MCP-1 2518 G/A (rs 1024611) in 296 patients diagnosed with prostate cancer and in 311 healthy controls from the same area. |
| T8 | 911-919 | Sentence | denotes | RESULTS: |
| T9 | 920-1094 | Sentence | denotes | Diagnosis of prostate cancer was significantly associated with TNF-A GA + AA genotype (OR, 1.61; 95% CI, 1.09-2.64) and RANTES GA + AA genotype (OR, 1.44; 95% CI, 1.09-2.38). |
| T10 | 1095-1223 | Sentence | denotes | A alleles in TNF-A and RANTES influenced prostate cancer susceptibility and acted independently of each other in these subjects. |
| T11 | 1224-1309 | Sentence | denotes | No epistatic effect was found for the combination of different polymorphisms studied. |
| T12 | 1310-1414 | Sentence | denotes | Finally, no overall association was found between prostate cancer risk and IL1-A or MCP-1 polymorphisms. |
| T13 | 1415-1426 | Sentence | denotes | CONCLUSION: |
| T14 | 1427-1629 | Sentence | denotes | Our results and previously published findings on genes associated with innate immunity support the hypothesis that polymorphisms in proinflammatory genes may be important in prostate cancer development. |
| T1 | 0-95 | Sentence | denotes | Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. |
| T2 | 96-107 | Sentence | denotes | BACKGROUND: |
| T3 | 108-218 | Sentence | denotes | Inflammation has been implicated as an etiological factor in several human cancers, including prostate cancer. |
| T4 | 219-354 | Sentence | denotes | Allelic variants of the genes involved in inflammatory pathways are logical candidates as genetic determinants of prostate cancer risk. |
| T5 | 355-578 | Sentence | denotes | The purpose of this study was to investigate whether single nucleotide polymorphisms of genes that lead to increased levels of pro-inflammatory cytokines and chemokines are associated with an increased prostate cancer risk. |
| T6 | 579-587 | Sentence | denotes | METHODS: |
| T7 | 588-910 | Sentence | denotes | A case-control study design was used to test the association between prostate cancer risk and the polymorphisms TNF-A-308 A/G (rs 1800629), RANTES-403 G/A (rs 2107538), IL1-A-889 C/T (rs 1800587) and MCP-1 2518 G/A (rs 1024611) in 296 patients diagnosed with prostate cancer and in 311 healthy controls from the same area. |
| T8 | 911-919 | Sentence | denotes | RESULTS: |
| T9 | 920-1094 | Sentence | denotes | Diagnosis of prostate cancer was significantly associated with TNF-A GA + AA genotype (OR, 1.61; 95% CI, 1.09-2.64) and RANTES GA + AA genotype (OR, 1.44; 95% CI, 1.09-2.38). |
| T10 | 1095-1223 | Sentence | denotes | A alleles in TNF-A and RANTES influenced prostate cancer susceptibility and acted independently of each other in these subjects. |
| T11 | 1224-1309 | Sentence | denotes | No epistatic effect was found for the combination of different polymorphisms studied. |
| T12 | 1310-1414 | Sentence | denotes | Finally, no overall association was found between prostate cancer risk and IL1-A or MCP-1 polymorphisms. |
| T13 | 1415-1426 | Sentence | denotes | CONCLUSION: |
| T14 | 1427-1629 | Sentence | denotes | Our results and previously published findings on genes associated with innate immunity support the hypothesis that polymorphisms in proinflammatory genes may be important in prostate cancer development. |
DisGeNET
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 25-31 | gene:6352 | denotes | RANTES |
| T1 | 79-94 | disease:C0376358 | denotes | prostate cancer |
| T2 | 50-55 | gene:7124 | denotes | TNF-A |
| T3 | 79-94 | disease:C0600139 | denotes | prostate cancer |
| T4 | 50-55 | gene:7124 | denotes | TNF-A |
| T5 | 79-94 | disease:C0376358 | denotes | prostate cancer |
| T6 | 40-45 | gene:6347 | denotes | MCP-1 |
| T7 | 79-94 | disease:C0600139 | denotes | prostate cancer |
| T8 | 40-45 | gene:6347 | denotes | MCP-1 |
| T9 | 79-94 | disease:C0376358 | denotes | prostate cancer |
| T10 | 25-31 | gene:6352 | denotes | RANTES |
| T11 | 79-94 | disease:C0600139 | denotes | prostate cancer |
| T12 | 757-760 | gene:3552 | denotes | IL1 |
| T13 | 847-862 | disease:C0600139 | denotes | prostate cancer |
| T14 | 788-793 | gene:6347 | denotes | MCP-1 |
| T15 | 657-672 | disease:C0376358 | denotes | prostate cancer |
| T16 | 788-793 | gene:6347 | denotes | MCP-1 |
| T17 | 657-672 | disease:C0600139 | denotes | prostate cancer |
| T18 | 788-793 | gene:6347 | denotes | MCP-1 |
| T19 | 847-862 | disease:C0376358 | denotes | prostate cancer |
| T20 | 788-793 | gene:6347 | denotes | MCP-1 |
| T21 | 847-862 | disease:C0600139 | denotes | prostate cancer |
| T22 | 757-760 | gene:3552 | denotes | IL1 |
| T23 | 847-862 | disease:C0376358 | denotes | prostate cancer |
| T24 | 757-760 | gene:3552 | denotes | IL1 |
| T25 | 657-672 | disease:C0600139 | denotes | prostate cancer |
| T26 | 757-760 | gene:3552 | denotes | IL1 |
| T27 | 657-672 | disease:C0376358 | denotes | prostate cancer |
| T28 | 700-705 | gene:7124 | denotes | TNF-A |
| T29 | 657-672 | disease:C0376358 | denotes | prostate cancer |
| T30 | 728-734 | gene:6352 | denotes | RANTES |
| T31 | 657-672 | disease:C0600139 | denotes | prostate cancer |
| T32 | 700-705 | gene:7124 | denotes | TNF-A |
| T33 | 657-672 | disease:C0600139 | denotes | prostate cancer |
| T34 | 728-734 | gene:6352 | denotes | RANTES |
| T35 | 657-672 | disease:C0376358 | denotes | prostate cancer |
| T36 | 1040-1046 | gene:6352 | denotes | RANTES |
| T37 | 933-948 | disease:C0600139 | denotes | prostate cancer |
| T38 | 1040-1046 | gene:6352 | denotes | RANTES |
| T39 | 933-948 | disease:C0376358 | denotes | prostate cancer |
| T40 | 983-988 | gene:7124 | denotes | TNF-A |
| T41 | 933-948 | disease:C0376358 | denotes | prostate cancer |
| T42 | 983-988 | gene:7124 | denotes | TNF-A |
| T43 | 933-948 | disease:C0600139 | denotes | prostate cancer |
| T44 | 1118-1124 | gene:6352 | denotes | RANTES |
| T45 | 1136-1151 | disease:C0600139 | denotes | prostate cancer |
| T46 | 1118-1124 | gene:6352 | denotes | RANTES |
| T47 | 1136-1151 | disease:C0376358 | denotes | prostate cancer |
| T48 | 1108-1113 | gene:7124 | denotes | TNF-A |
| T49 | 1136-1151 | disease:C0600139 | denotes | prostate cancer |
| T50 | 1108-1113 | gene:7124 | denotes | TNF-A |
| T51 | 1136-1151 | disease:C0376358 | denotes | prostate cancer |
| T52 | 1394-1399 | gene:6347 | denotes | MCP-1 |
| T53 | 1360-1375 | disease:C0600139 | denotes | prostate cancer |
| T54 | 1394-1399 | gene:6347 | denotes | MCP-1 |
| T55 | 1360-1375 | disease:C0376358 | denotes | prostate cancer |
| T56 | 1385-1388 | gene:3552 | denotes | IL1 |
| T57 | 1360-1375 | disease:C0600139 | denotes | prostate cancer |
| T58 | 1385-1388 | gene:3552 | denotes | IL1 |
| T59 | 1360-1375 | disease:C0376358 | denotes | prostate cancer |
| R1 | T0 | T1 | associated_with | RANTES,prostate cancer |
| R2 | T2 | T3 | associated_with | TNF-A,prostate cancer |
| R3 | T4 | T5 | associated_with | TNF-A,prostate cancer |
| R4 | T6 | T7 | associated_with | MCP-1,prostate cancer |
| R5 | T8 | T9 | associated_with | MCP-1,prostate cancer |
| R6 | T10 | T11 | associated_with | RANTES,prostate cancer |
| R7 | T12 | T13 | associated_with | IL1,prostate cancer |
| R8 | T14 | T15 | associated_with | MCP-1,prostate cancer |
| R9 | T16 | T17 | associated_with | MCP-1,prostate cancer |
| R10 | T18 | T19 | associated_with | MCP-1,prostate cancer |
| R11 | T20 | T21 | associated_with | MCP-1,prostate cancer |
| R12 | T22 | T23 | associated_with | IL1,prostate cancer |
| R13 | T24 | T25 | associated_with | IL1,prostate cancer |
| R14 | T26 | T27 | associated_with | IL1,prostate cancer |
| R15 | T28 | T29 | associated_with | TNF-A,prostate cancer |
| R16 | T30 | T31 | associated_with | RANTES,prostate cancer |
| R17 | T32 | T33 | associated_with | TNF-A,prostate cancer |
| R18 | T34 | T35 | associated_with | RANTES,prostate cancer |
| R19 | T36 | T37 | associated_with | RANTES,prostate cancer |
| R20 | T38 | T39 | associated_with | RANTES,prostate cancer |
| R21 | T40 | T41 | associated_with | TNF-A,prostate cancer |
| R22 | T42 | T43 | associated_with | TNF-A,prostate cancer |
| R23 | T44 | T45 | associated_with | RANTES,prostate cancer |
| R24 | T46 | T47 | associated_with | RANTES,prostate cancer |
| R25 | T48 | T49 | associated_with | TNF-A,prostate cancer |
| R26 | T50 | T51 | associated_with | TNF-A,prostate cancer |
| R27 | T52 | T53 | associated_with | MCP-1,prostate cancer |
| R28 | T54 | T55 | associated_with | MCP-1,prostate cancer |
| R29 | T56 | T57 | associated_with | IL1,prostate cancer |
| R30 | T58 | T59 | associated_with | IL1,prostate cancer |
DisGeNET5_gene_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 19099590-0#50#55#gene7124 | 50-55 | gene7124 | denotes | TNF-A |
| 19099590-0#79#94#diseaseC0376358 | 79-94 | diseaseC0376358 | denotes | prostate cancer |
| 19099590-0#79#94#diseaseC0600139 | 79-94 | diseaseC0600139 | denotes | prostate cancer |
| 19099590-4#200#205#gene6347 | 788-793 | gene6347 | denotes | MCP-1 |
| 19099590-4#69#84#diseaseC0376358 | 657-672 | diseaseC0376358 | denotes | prostate cancer |
| 19099590-4#69#84#diseaseC0600139 | 657-672 | diseaseC0600139 | denotes | prostate cancer |
| 19099590-4#259#274#diseaseC0376358 | 847-862 | diseaseC0376358 | denotes | prostate cancer |
| 19099590-4#259#274#diseaseC0600139 | 847-862 | diseaseC0600139 | denotes | prostate cancer |
| 19099590-6#23#29#gene6352 | 1118-1124 | gene6352 | denotes | RANTES |
| 19099590-6#41#56#diseaseC0376358 | 1136-1151 | diseaseC0376358 | denotes | prostate cancer |
| 19099590-6#41#56#diseaseC0600139 | 1136-1151 | diseaseC0600139 | denotes | prostate cancer |
| 19099590-8#75#78#gene3552 | 1385-1388 | gene3552 | denotes | IL1 |
| 19099590-8#50#65#diseaseC0376358 | 1360-1375 | diseaseC0376358 | denotes | prostate cancer |
| 19099590-8#50#65#diseaseC0600139 | 1360-1375 | diseaseC0600139 | denotes | prostate cancer |
| 50#55#gene712479#94#diseaseC0376358 | 19099590-0#50#55#gene7124 | 19099590-0#79#94#diseaseC0376358 | associated_with | TNF-A,prostate cancer |
| 50#55#gene712479#94#diseaseC0600139 | 19099590-0#50#55#gene7124 | 19099590-0#79#94#diseaseC0600139 | associated_with | TNF-A,prostate cancer |
| 200#205#gene634769#84#diseaseC0376358 | 19099590-4#200#205#gene6347 | 19099590-4#69#84#diseaseC0376358 | associated_with | MCP-1,prostate cancer |
| 200#205#gene634769#84#diseaseC0600139 | 19099590-4#200#205#gene6347 | 19099590-4#69#84#diseaseC0600139 | associated_with | MCP-1,prostate cancer |
| 200#205#gene6347259#274#diseaseC0376358 | 19099590-4#200#205#gene6347 | 19099590-4#259#274#diseaseC0376358 | associated_with | MCP-1,prostate cancer |
| 200#205#gene6347259#274#diseaseC0600139 | 19099590-4#200#205#gene6347 | 19099590-4#259#274#diseaseC0600139 | associated_with | MCP-1,prostate cancer |
| 23#29#gene635241#56#diseaseC0376358 | 19099590-6#23#29#gene6352 | 19099590-6#41#56#diseaseC0376358 | associated_with | RANTES,prostate cancer |
| 23#29#gene635241#56#diseaseC0600139 | 19099590-6#23#29#gene6352 | 19099590-6#41#56#diseaseC0600139 | associated_with | RANTES,prostate cancer |
| 75#78#gene355250#65#diseaseC0376358 | 19099590-8#75#78#gene3552 | 19099590-8#50#65#diseaseC0376358 | associated_with | IL1,prostate cancer |
| 75#78#gene355250#65#diseaseC0600139 | 19099590-8#75#78#gene3552 | 19099590-8#50#65#diseaseC0600139 | associated_with | IL1,prostate cancer |
DisGeNet-2017-sample
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T554 | 788-793 | gene:6347 | denotes | MCP-1 |
| T555 | 657-672 | disease:C0376358 | denotes | prostate cancer |
| T556 | 847-862 | disease:C0376358 | denotes | prostate cancer |
| R1 | T554 | T555 | associated_with | MCP-1,prostate cancer |
| R2 | T554 | T555 | associated_with | MCP-1,prostate cancer |
| R3 | T554 | T556 | associated_with | MCP-1,prostate cancer |
| R4 | T554 | T556 | associated_with | MCP-1,prostate cancer |